Cargando…

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives

Diabetes is the leading cause of chronic and end stage kidney disease globally. Despite recent advances in therapies for diabetic kidney disease (DKD), there remains a critical need for additional options to improve renal and cardiovascular outcomes. Mineralocorticoid overactivation contributes to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaikh, Aisha, Ray, Justina, Campbell, Kirk N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346301/ https://www.ncbi.nlm.nih.gov/pubmed/35937973 http://dx.doi.org/10.2147/TCRM.S325916

Ejemplares similares

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
por: Ashjian, Emily, et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
por: Quist, Sara W., et al.
Publicado: (2023)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria
por: Bramlage, Peter, et al.
Publicado: (2023)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA
por: Zhang, Rong M
Publicado: (2023)

Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Publicado: (2022)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
por: Rossing, Peter, et al.
Publicado: (2022)

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhang, Ming-Zhu, et al.
Publicado: (2022)

Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis
por: Yasmin, Farah, et al.
Publicado: (2023)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
por: Rossing, Peter, et al.
Publicado: (2022)

GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone
por: Pollard, Celina M, et al.
Publicado: (2022)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
por: González-Blázquez, Raquel, et al.
Publicado: (2018)

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2022)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus
por: Jyotsna, FNU, et al.
Publicado: (2023)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021)

Enantioselective Total Synthesis of (−)‐Finerenone Using Asymmetric Transfer Hydrogenation
por: Lerchen, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bq5j9530gobqrheu2qvu6e597f